The 340B program “attracts hospitals, clinics and for-profit pharmacies because it is easy for them to use the program as a slush fund to benefit their bottom lines, diverting money that could be used to help patients get better care
…
Month: March 2021
Vermont State Attorney General T.J. Donovan (D) has issued a subpoena to drug manufacturer Sanofi “seeking certain information about Sanofi’s 340B program participation,” the company disclosed last week.
Neither Sanofi nor Donovan’s office have responded to requests for comment. Sanofi
…
Health insurance company Humana has begun sending pharmacy provider agreements for 2022 to 340B-participating pharmacies, with claims-identification and data-reporting conditions that some 340B providers say are unsettling. They say the agreements are to be signed and returned within 30 days
…
The U.S. Senate voted 50 to 49 along party lines early Saturday morning to approve an amended version of the House’s $1.9 trillion COVID-19 relief bill. According to House Majority Leader Steny Hoyer’s (D-Md.) office, the House could vote on
…
Hospital groups that recently filed a motion to intervene in opposition to drug manufacturer Eli Lilly’s lawsuit against the federal government over 340B contract pharmacy requirements also are trying to intervene in similar suits against the government by manufacturers AstraZeneca,
…
The U.S. Senate Finance Committee yesterday split 14-14 along party lines on whether to favorably report California Attorney General Xavier Becerra’s nomination to serve as U.S. Health and Human Services (HHS) secretary to the full Senate.
There is a 50-50
…
SPONSORED CONTENT
Acentrus Specialty hosted its first Acentrus Specialty Conference on January 12-13, 2021, which brought together pharmacists, manufacturers, and suppliers to examine the challenges, opportunities, and best practices in advancing health system specialty pharmacy practice. A pharmacy paradigm shift is under way, as Integrated Delivery Networks (IDNs) are partnering to grow their specialty pharmacy operations.
“The conference
…
More than 70 percent of U.S. spending on top-selling “partial orphan drugs”—drugs for rare diseases that also are approved to treat common diseases—is for non-orphan indications, a study in latest edition of Health Affairs concludes.
Makers of partial orphan drugs
…
In a concession to drug companies, Senate Democrats reportedly have agreed to delay by one year—from Jan. 1, 2023 to Jan. 1, 2024—the effective date of language in the $1.9 trillion COVID-19 relief bill that might lead to 340B ceiling
…